RESEARCH STUDIES & Clinical Trials

Clinical Trial ID: NCT02775383 The National Myelodysplastic Syndromes (MDS) Study

Status

Open

Description

Multi-center, prospective cohort study enrolling patients from centers in the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). The accrual period is 5+ years. After central pathology review of registered participants, approximately 2,000 cases of MDS or MDS/MPN overlap disorders, and 500 cases of ICUS will be identified for the longitudinal study cohort and up to 1000 cases will be identified for the cross-sectional cohort. No more than 3500 total participants will be registered. Participants in the longitudinal cohort may be followed for life. The goal of the National MDS Study is to establish a publicly available resource to facilitate the study of MDS natural history. This will be accomplished through: 1) Creation of a multi-institutional, longitudinal collection of consistently processed and clinically well-annotated blood and tissue specimens collected prospectively from participants with MDS and participants with idiopathic cytopenia of undetermined significance (ICUS); and 2) Support for investigator-initiated studies of MDS that will have high-impact for MDS patients, including basic science, clinical, health outcomes and epidemiological research.

Objective

1. To develop a high-quality clinical database containing clinical history, including environmental exposure history, presenting signs and symptoms, diagnostic testing results, co-existing diseases, therapies and response to therapies, disease progression, quality of life and survival. 2. To develop a high-quality biorepository linked to the clinical data that will facilitate diverse studies, including genetic, epigenetic, immunologic, proteomic, and cell-functional and cell-phenotypic studies through the development of (details described further in the Manual of Procedures): - Central communication with the biorepository to ensure timely and accurate collections and biospecimen data appended to the clinical database. - Defined standard operating procedures for the collection, processing, storage and distribution, with special emphasis on processing protocols fit-for-purpose to sample requirements for downstream testing. - Quality management procedures to ensure minimal numbers of errors in the management of the biospecimens. 3. To facilitate broad use of these linked data and specimens to support studies focused on: - Improving diagnostic accuracy, risk-stratification and prognostication, and medical decision-making in MDS; - Understanding quality of life and its relationship to changing disease and treatment status - Understanding the pathogenesis of MDS and diverse MDS subtypes, including genetic, epigenetic, immunologic mechanisms; - Optimizing treatment strategies for specific subtypes of MDS; - Identifying novel biomarkers for MDS outcomes; and - Identifying novel targets for therapeutic interventions in MDS.

Treatment

Longitudinal: Participants with MDS, MDS/MPN overlap disorder, or ICUS who are followed long term Cross-sectional: Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only

Conditions

Other

Phases

III

Therapies

Drugs

Age Group

Adult

Main Investiagtor

Gorak, Edward

Practice

MDS

Scope

National

Participating Institutions

Baptist MD Anderson Cancer Center

Eligibility

Inclusion Criteria: - Suspected (e.g., persistent unexplained cytopenia, circulating peripheral blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic work-up with planned bone marrow assessments, or diagnosed with de novo or therapy-related MDS within 6-months of enrollment per the World Health Organization (WHO) criteria1 and undergoing clinical evaluation and planned bone marrow assessments to confirm MDS or to evaluate disease status - Bone marrow aspirate expected to be performed within 1 week of registration, and in all cases must be performed no later than 4 weeks after enrollment - Age 18 or older - B12 level, serum folate, ferritin, and Thyroid-Stimulating Hormone (TSH) tests performed in prior 6 months Exclusion Criteria: - Prior treatment for MDS at entry and through the time of the entry bone marrow aspirate - Treatment with hematopoietic growth factors in prior 6 months - Diagnosis of a solid tumor or hematologic malignancy within two years prior to enrollment except for in situ cancer of the skin (basal or squamous cell), cervix, bladder, breast, or prostate - Treatment with radiation therapy in the two years prior to registration - Non-hormonal treatment for malignancy within the two years prior to registration - Established hereditary bone marrow failure syndrome - Known primary diagnosis of aplastic anemia, classical paroxysmal nocturnal hemoglobinuria, amegakaryocytic thrombocytopenic purpura, or large granular lymphocyte leukemia - Enrolled in the Connect® MDS/AML Disease Registry (NCT01688011)

Nct ID Number

NCT02775383

Secondary Trial ID Number

NHLBI-MDS

Keywords

Observational

More Information

clinicaltrials.gov

“The support team gave not only me but my family a sense of peace.”

—David Smith, Patient

At Baptist MD Anderson, you can rely on our cancer experts to deliver the complex, coordinated care needed to address your condition. Learn more about Patricia’s story as well as others from our patients.